```
1. 2. 1. 1.
                  1.
                           1.
                            1
                    2
                                              가
                 ١.
                                                               ePTFE
                                                                          8 - 11)
                                                                                    Ш
Melcher<sup>1)</sup>가
                                                                           가
                                   가
                                              ePTFE가
                                                                           ) 가
                                                         12),
                 가
                                                                        가
         가
                                     2-3)
                                                13 - 20)
                          70 - 80%
                      4-7)
                                                                                  21)
                  ePTFE(expanded poly -
tetrafluoroethylene)
                                       가
                         가
                      가
                                                                         가
                                                            collagen<sup>20,22)</sup>,
                                                                                  (dura
                                                             24),
                                              mater)<sup>23)</sup>,
```

polylactic		
acid(PLA), polyglycolic acid(PGA)		
poly(glycolide - lactide)		
	•	가
poly( - hydroxy acid) . PGA/PLA		
(Resolut ) 26 - 28)	50%	40),
ePTFE		
	80%가 41)	
, citric acid ester		
PLA (Guidor )		10)
TEA (Guidol )		,
		가
29,30).		
Polyglactin 910(Vicryl ) ePTFE	가 42,43).	
Guidor 31 -		가
35)		
(BioMesh	44)	
\ <b>=D.</b>	· · /.	
, , , ) FDA		
PLA/PGA/ PLGA lactide gly -	(DFD	BA: Demineralized
colide polylactic acid	freeze - dried bone allog	raft) ,
polylactic - glycolic acid sodium	,	
citrate 가 , sodium	,	가
citrate	45)	• 1
	· ·	
. BioMesh	가	
3 - 4	46 - 49) フト	
	ePTFE 가 , tricalc	ium phosphate
36,37).	DFDBA 46)	ePTFE
4	(31%)	
8 가	72%	
0 /1		
00)	,	
36).	ePTFE DFDBA	
	ePTFE	
(Resolut :PGA/PLA membrane,	, 가,	1
Guidor: PLA membrane blended with citric	47)	
acid ester) 37).		
acid estery	48,49) <b>DEDBA</b>	
	, DI DDA	
, II	II	6
가 .	가	<sup>48)</sup> collagen
가	membrane	DFDBA가 collagen
38,39) 40 - 42)	membrane	,

Table	1.	Distrib	ution	and	charac	teristics	of
	á	alveolar	bone	e defe	ects		

Type of Defect	Mx	Mn	Total
Intrabony Defect	21	7	28
Furcation II	11	28	39
Furcation III	9	16	25
Total	41	51	92

, 가 가 <sup>49)</sup>.

II III 가

가 . II.

1.

3 , 가 , 가

4mm 가 가

. , 가 32 ( 22 .

10 ; 16 , 16 ) 46.5 ( : 25 - 63 ) , 92 フト . フト 11 , フト 9 , , 21 , 7 2 3 (Table 1). 46 43 , 49

,

2.

(hygienic phase)

92 'BioMesh alone' 'BioMesh plus DFDBA' 2

,

.

1) ( , , , , , ) . (PD) (GR)

(CAL)

1mm .
periodontal manual probe(CP12, Hu Friedy, Chicago, IL) .
(PI) Silness and L e<sup>50)</sup>

(GI) L e and Silness<sup>51)</sup>

```
가
                 가
                          2
                                                                     3
                           1999
                                                         tetracycline HCI
                                  3
                                                                            1:4
6
                                               DFDBA
                                                                                   (水和)
     1:80,000
                                                               (Augmentin: amoxycillin
5<sub>mm</sub>
                                              /clavulanate potassium 375mg,
                                                      ) 5
                                               0.1% chlorhexidine digluconate
                                                                             2
                                                        가
                              .tetracycline
hydrochloride
                                               Ibuprofen 200mg
                                                                             . 2
                       (BioMesh)
                                                              (COE - PAK™, GC America
                                               Inc., IL, USA)
                                                      1
              3<sub>mm</sub>
                                              52) 0.1% chlorhexidine digluconate
                         Surgisorb(
                                                                  1, 2, 3, 4, 6, 8
                 DFDBA(DEMBONETM,
Pacific coast tissue bank, CA, USA)
                                                 10 - 12
tetracycline HCI
                                                2)
                                                                    SPSS software(SPSS
                            tetracycline
                                               Inc., Chicago, IL, USA)
              tetracycline HCI가
                                                   ±
```

Table 2. Comparsion of clinical between baseline and post - op 4 months(Smokers/Non - smokers)

Parameter		Non - Smokers			Smokers	
	Baseline	4 months	Significance	Baseline	4 months	Significance
PD	6.41 ± 1.48	2.15 ± 1.17	Y(.000)	6.61 ± 1.29	2.09 ± 1.03	Y(.000)
GR	1.87 ± 1.12	$2.83 \pm 1.54$	Y(.000)	$1.63 \pm 1.06$	$3.22 \pm 1.33$	Y(.000)
CAL	$8.28 \pm 1.95$	$4.98 \pm 1.73$	Y(.000)	$8.24 \pm 1.45$	$5.30 \pm 1.68$	Y(.000)
PI	$0.76 \pm 0.85$	$0.13 \pm 0.40$	Y(.000)	$0.96 \pm 0.84$	$0.28 \pm 0.54$	Y(.000)
GI	$0.96 \pm 0.89$	$0.09 \pm 0.28$	Y(.000)	$1.41 \pm 0.75$	$0.20 \pm 0.40$	Y(.000)

PD: Pocket depth, GR: Gingival recession, CAL: Clinical attachment level, PI: Plaque index, GI: Gingival

Table 3. Changes of clinical indices with respect to smoking

	Non - Smokers	Smokers	Significance
PD	4.26 ± 1.60	4.52 ± 1.41	N(.409)
GR	$0.96 \pm 1.01$	1.59 ± 1.29	Y(.011)
CAL	$3.30 \pm 1.84$	$2.93 \pm 1.47$	N(.289)

PD: Reduction in pocket depth, GR: Increase in gingival recession

CAL: Increase in clinical attachment level (unit: mm)




Figure 1. Changes of clinical indices with respect to smoking

Table 4. Comparison of clinical indices between baseline and post-op 4 months(Biomesh+DFDBA/Biomesh alone)

Parameter	В	iomesh+DFDBA	1		Biomesh alon	е
. arameter	Baseline	4months	Significance	Baseline	4months	Significance
PD	6.69 ± 1.39	2.06 ± 1.07	Y(.000)	6.30 ± 1.37	2.19 ± 1.14	Y(.000)
GR	1.69 ± 1.16	$3.08 \pm 1.57$	Y(.000)	1.81 ± 1.18	$2.95 \pm 1.31$	Y(.000)
CAL	$8.39 \pm 1.75$	$5.14 \pm 1.73$	Y(.000)	$8.12 \pm 1.66$	$5.14 \pm 1.70$	Y(.000)
PI	$0.86 \pm 0.84$	$0.18 \pm 0.49$	Y(.000)	$0.86 \pm 0.86$	$0.23 \pm 0.48$	Y(.000)
GI	$1.12 \pm 0.83$	$0.14 \pm 0.35$	Y(.000)	$1.26 \pm 0.88$	$0.14 \pm 0.35$	Y(.000)

PD: Pocket depth, GR: Gingival recession, CAL: Clinical attachment level, PI: Plaque index, GI: Gingival

Table 5. Changes of clinical indices with respect to bone graft

	Biomesh+DFDBA	Biomesh alone	Significance
PD	4.63 ± 1.54	4.12 ± 1.43	N(.101)
GR	$1.39 \pm 1.30$	1.14 ± 1.06	N(.323)
CAL	$3.24 \pm 1.73$	$2.98 \pm 1.60$	N(.443)

PD: Reduction in pocket depth, GR: Increase in gingival recession

CAL: Increase in clinical attachment level(4 months, unit: mm)




Figure 2. Changes of clinical indices with respect to bone graft

Table 6. Comparison of clinical indices with respect to smoking and bone graft

	Non - Si	mokers	Smokers	
	Biomesh+DFDBA	Biomesh alone	Biomesh+DFDBA	Biomesh alone
PD	4.42 ± 1.85	4.09 ± 1.34	4.84 ± 1.21	4.41 ± 1.56
GR	1.04 ± 1.11	$0.86 \pm 0.94$	$1.72 \pm 1.43$	1.43 ± 1.12
CAL	$3.38 \pm 1.99$	$3.23 \pm 1.74$	$3.12 \pm 1.51$	2.71 ± 1.42

PD: Reduction in pocket depth, GR: Increase in gingival recession CAL: Increase in clinical attachment level (4 months, unit: mm)




Figure 3. Chmparison of clinical indices with respect to smoking and bone graft

Table 7. Changes in clinical attachment level with respect to exposure of barrier membrane

	Exposure	Non - Exposure	Significance
No of Defects	31	61	N/ E2E)
CAL	$2.97 \pm 1.69$	$3.20 \pm 1.75$	N(.535)

CAL: Increase in clinical attachment level(4 months, unit: mm)




Figure 4. Changes in clinical attachment level with respect to exposure of barrier membrane

```
(p<0.001).
6.30mm 4 2.19mm ,
6.69mm 2.06mm
, 8.12mm
5.14mm , 8.39mm 5.14mm
.
```

: 4.63, : 4.12mm) ( : 3.24, : 2.98mm)

(Table 5, Figure 2).

(4.09mm, 4.42mm), (0.86mm, 1.04mm), (3.23mm, 3.38mm)

(4.14mm, 4.84mm), (1.43mm,

```
1.72mm), (2.71mm, 3.12mm)

フト .

, (4.14mm, 4.09mm),

(1.43mm, 0.86mm),

(2.71mm, 3.23mm) フト

(4.84mm,
```

4.42mm), (1.72mm, 1.04mm), (3.12mm, 3.38mm) 가

Table 6 Figure 3 가 ,

. 가 ,

3 - 4 92 31 (33%) 25 . 2.97mm

. 2.97mm 가 3.2mm 가

> (Table 7, Figure 4). 가

VI.

(

```
4
                                                                   가
          가
                                                        가
        가
          가
                                                        가
                                             1
          가
                                  가
                                                            가
                                                     58).
          38 - 40,43,53)
                              54)
      55)
                                                              46 - 49,59)
                                                  가
  56)
                               10)
                                                           가
  43)
                                               가
                                                        59)
                                                                                   60).
                                             MaClain
                                                       Schallhorn
                                                                          가
                                  38,44)
                                                    가
 Tonetti
                                                                       , Anderegg
                                       가
    1
                              가
                                                                           . Schults
       50%
                                             Gager<sup>61)</sup>
2.1mm,
                 5.2mm). Rosen
                                                          (Polyglactin 910)
DFDBA
                                                   Collagen membrane DFDBA
                                 : 2.7mm
        : 3.4mm).
                      Luepke
                                42)
                                                    21,62)
                                                                 가
                  DFDBA
                          가
                                                         Caffesse 63)
             가
                                                  가
DFDBA
                           가
                                                                 가
                                                              . Mellado
```

	가			
a a lla e a a e		. Chen 49)	tetracycline HCl	67,68)
	nembrane nembrane	DFDBA가	powder 4:1	tetracycline HCI
,	,		69,70)	in vitro
		•	가	
			•	
가				
,			·	
,	,			4
,	가		·	가
	가			
	· 가		32,33).	
26).	8			
	Ü			
가			가	
36,37).				
			32,35,65)	
			•	
			<sup>71-75</sup> ). Demolon	75)
				moxicillin/clavu -
		49,65)	lanate potassium	
			, 가 <sup>71)</sup> .	
	DFDBA가		·	
	(os	teoblastic pene -	_,	52,76).
tration)	가	63,64,66).	가	

가 86) 77 - 82) 가 가 21,47) 가 가 가 가 63,66) 8,21,46,47,49,60,64,66,83) BioMesh 3 - 4 ( : 1.59mm, : 0.96mm) 36,37) 4 가 가 8 가 Bragger 84) 3 12 Christgau 33) 12 가 6 77,82,83). 가 가 BioMesh 2 3 가 33%가 1 - 2mm 10,30,40,85) 가

가 27,31,64,87) 가 1 4 Tepaart 29) 10 6 가 Laurell 80,88) 10 66 32 5 88)가 , Falk 30) 203 54 (27%)가 2 (50%)가 4 2 102 4 가 Guidor PLA membrane blended with . PGA/PLA citric acid ester) 26) (Resolut) Caffesse 12 5 가 92 31 (33%)가 25 64) .Mellado 30) 2) Caton 3 Caton<sup>89)</sup> Zappa

**ePTFE** 

3

6

가 가 가 가 가 가 V.

4

- 1. Melcher AH. On the repair potential of Periodontal tissue. Journal of Periodontology 1976;47:256 260
- Caton J, Frantz B, Greenstein G, Ploson A, Hoffman P, Zappa U. Synthetic biodegradable barrier for regeneration in human periodontal defects. Journal of Dental Research 1990;69(special issue):275
- Line SE, Ploson A, Zander H. Relationship between periodontal injury, selective cell repopulation and ankylosis. Journal of Periodontology 1974;45: 725 - 730
- Cortellini P, Pini Prato G, Tonetti M. Periodontal regeneration of human infrabony defects. 1. clinical measures. Journal of Periodontology 1993;64: 254 - 260
- Cortellini P, Pini Prato G, Tonetti M Periodontal regeneration of human infrabony defects. 2. Re - entry proce dures and bone measures. Journal of

- Periodontology 1993;64:261 268
- 6. Cortellini P & Bowers GM. Periodontal regeneration of intrabony defects. International Journal of Periodontics and Restorative Dentistry 1995:15:128 147
- 7. Minabe M. Selective periodontal tissue reconstructive therapy. Journal of Periodontology 1991;62:171 179
- Lekovic V, Kenny, EB, Kovacevic K,Carranza Jr FA. Evaluation of guided tissue regeneration in class furcation defects. A clinical re-entry study. Journal of Periodontology 1989;60:694 -698
- Caffesse R, Smith B, Duff B, Morrison E, Merrill D, Becker W. Class furcations treated by guided tissue regeneration in humans. Journal of Periodontology 1990;61:510 - 514
- Machtei EE, Cho MI, Dunford R, Norderyd J, Zambon JJ, Genco RJ. Clinical, microbiological, and histological factors which influence the success of regenerative periodontal therapy. Journal of Periodontology 1994;65:154-161
- 11. Mellonig, JT, Seamons BC, Gray JL & Towle HJ. Clinical evaluation of guided tissue regeneration in the treatment of grade molar furcation invasions. International Journal of Periodontics and Restorative Dentistry 1994;14:255 271
- Scantlebury TV. A decade for technology development for guided tissue regeneration. Journal of Periodontology 1993;64:1129 - 1137
- 13. Fleisher N, Waal HD, Bloom A.

- Regeneration of lost attachment apparatus in the dog using Vicryl absorbable mesh(Polyglactin 910). International Journal of Periodontics and Restorative Dentistry 1988:8:45 54
- 14. Minabe M, Kodama T, Kogus T, Tamura T, Hori T, Watanabe Y, Miyata T. Different cross - linked types of collagen implanted in rat palatal gingiva. Journal of Periodontology 1989;60:35 -43
- Kodama T, Minabe M, Hori T, Watanabe Y. The effect of various concentrations of collagen barrier on periodontal wound healing. Journal of Periodontology 1989;60:205 - 210
- 16. Pitaru S, Tal H, Soldinger M, Azar - Avidan O, Noff M. Collagen mem branes prevent the apical migration of epithelium during periodontal wound healing. Journal of Periodontal Research 1987:22:331 - 333
- Chung KM, Salkin LM, Stein MD, Freedman AL. Clinical evaluation of a biodegradable collagen membrane in guided tissue regeneration. Journal of Periodontology 1990;61:732 - 736
- Hugoson A, Ravald N, Fornell J, Johard G, Teiwik A, Gottlow J. Treatment of class II furcation involve ments in humans with bioresorbable and nonresorbable guided tissue regenera tion barriers. A randomized multi - center study. Journal of Periodontology 1995;66:624 - 634
- Van Swol RL, Ellinger R, Pfeifer J, Barton NE, Blumenthal N.Collagen membrane barrier therapy to guide regeneration in Class II furcations in

- humans. Journal of Periodontology 1993:64:622 - 629
- 20. Blumenthal NM. A clinical comparison of collagen membranes with e-PTFE membranes in the treatment of human mandibular buccal class II furcation defects. Journal of Periodontology 1993;64:925 - 933
- 21. Blumenthal N, Steinberg J. The use of collagen membrane barriers in conjunction with combined demineralized bone collagen gel implants in human infrabony defects. Journal of Periodontology 1990;61:319 327
- 22. Black BS, Gher ME, Sandifer JB, Fucini SE, Richardson AC. Comparative study of collagen and Expanded polyte-trafluoroethylene me mbranes in the treatment of human class II furcation defects. Journal of Periodontology 1994; 65:598 604
- 23. Yukna RA. Clinical human comparison of expanded polytetra - fluoroethylene barrier membrane and freeze - dried dura mater allografts for guided tissue regeneration of lost periodontal support. I. Mandibular molar Class II furcations. Journal of Periodontology 1992;63:431 - 442
- 24. Card SJ, Caffesse RG, Smith BA, Nasjleti CE. New attachment following the use of a resorbable membrane in the treatment of periodontitis in dogs. International Journal of Periodontics and Restorative Dentistry 1989;9:58 - 69
- 25. Bouchard P, Ouhayoun JP, Nilveus RE. Expanded polytetrafluoroethylene membranes and connective tissue grafts support bone regeneration for closing

- mandibular Class II furcations. Journal of Periodontology 1993;64: 1193 - 1198
- 26. Caffesse RG, Mota LR, Quinones CR, Morrison EC. Clinical comparison of resorbable and non resorbable barriers for guided periodontal tissue regeneration. Journal of Clinical Periodontology 1997:24:747 752
- Bouchard P, Giaovannoli JL, Mattout C, Davarpanah M, Etienne D. Clinical evaluation of a bioabsorbable regenerative material in mandibular class furcation therapy. Journal of Clinical Periodontology 1997;24:511 - 518
- 28. Lindhe J, Pontoriero R, Berglundh T & Araujo M. The effect of flap man agement and bioresorbable occlu sive devices in GTR treatment of degree furcation defects. Journal of Clinical Periodontology 1995;22:276 283
- 29. Teparat T, Solt CW, Claman LJ, Beck RM. Clinical comparison of bioabsorbable barriers in guided tissue regeneration in the treatment of human intrabony defects. Journal of Periodontology 1998;69:632 - 641
- 30. Falk H, Laurell L, Ravald N, Teiwik A, Persson R. Guided tissue regeneration therapy of 203 consecu tively treated intrabony defects using a bioabsorbable matrix barrier. Clinical and radiographic findings. Journal of Periodontology 1997;68:571 581
- Caton J, Greenstein G, Zappa U. Synthetic bioabsorbable barrier for regeneration in human periodontal defects. Journal of Periodontology 1994;65: 1037 - 1045
- 32. Christgau M, Schmalz G, Reich E,

- Wenzel A. Clinical and radiographical split mouth study on resorbable ver sus non resorbable GTR membranes. Journal of Clinical Periodontology 1995:22:306 315
- Christgau M, Bader N, Schmalz G, Hiller KA, Wenzel A. GTR therapy of intrabony defects using 2 different bioresorbable membranes: 12 - month results. Journal of Clinical Periodont ology 1998;25:499 - 509
- 34. Eickholz P, Lenhard M, Benn DK, Staehle HJ. Periodontal surgery of vertical bony defects with or without synthetic bioabsorbable barriers. 12 - month results Journal of Periodont - ology 1998;69:1210 - 1217
- 35. Eickholz P, Kim T S, Holle F. Guided tissue regeneration with non resorbable and biodegradable barriers: 6 months results. Journal of Clinical Periodontology 1997;24:92 101

- 38. Haber J, Wattles J, Crowley M, Manderll R, Joshipura K & Kent R.Evidence for cigarette smoking as a major risk factor for periodontitis. Journal of Periodontology 1993;21: 91-97
- 39. Preber H & Bergstrom, J. Effect of cigarette smoking on periodontal healing

- following surgical therapy. Journal of Clinical Periodontology 1990;17:324 328
- 40. Tonetti M, Pini-Prato G & Cortellini P. Effect of cigarette smoking on periodontal healing following GTR in infrabony defects. A preliminary retrospective study. Journal of Clinical Periodontology 1995;22:229 234
- 41. Rosenberg ES, Cutler SA. The effect of cigarette smoking on the long-term success of guided tissue regeneration: a preliminary study. Ann R Australas Coll Dent Surg 1994;12:89-93
- 42. Luepke PG, Mellonig JT, Brunsvold MA. A clinical evaluation of a biore sorbable barrier with and without decal-cified freeze dried bone allograft in the treatment of molar furcations. Journal of Clinical Periodontology 1997;24:440 446
- 43. Cortellini P, Pini Prato G, Tonetti M. Periodontal regeneration of human intrabony defects. Effect of oral hygiene on long term stability. Journal of Clinical Periodontology 1994;21:606 610
- 44. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, Norderyd OM, Genco RJ. Assessment of risk indicators for periodontal disease. I. Risk indicators for attachment loss. Journal of Perio dontology 1994;65:260 267
- 45. Bowers GM, Chadroff B, Carnevale R, Mellonig J, Corio R, Emerson J, Stevens M, Romberg E. Histologic evaluation of new attachment apparatus formation in humans. Part I. Journal of

- Perio dontology 1989;60:664 674
- 46. Schallhorn RG & McClain PK. Combined osseous composite grafting, root conditioning and guided tissue regeneration. International Journal of Periodontics and Restorative Dentistry 1988;8:8 - 31
- 47. Anderegg C, Martin S, Gray J, Mellonig J & Gher M. Clinical evaluation of the use of decalcified freeze dried bone allograft with guided tissue regeneration in the treatment of molar furcation invasions. Journal of Periodontology 1991: 62:264 268
- 48. Wallace SC, Gellin RG, Miller MC & Mishkin DJ. Guided Tissue regeneration with and without decalcified freeze dried bone in mandibular class furca tion invasions. Journal of Periodontology 1994;66: 244 254
- 49. Chen CC, Wang HL, Smith F, Glickman GN, Shyr Y, O'Neal RB. Evaluation of a collagen membrane with and without bone grafts in treating periodontal intrabony defects. Journal of Periodontology 1995;66: 838 847
- 50. Silness P, L e H. Periodontal dis ease in pregnancy. Acta Odontol Scand 1964;22:121
- L e H and Silness P. Periodontal disease in pregnancy. Acta Odontol Scand 1963;21:533
- 52. Polson AM, Garrett S, Stoller NH, Greenstein G, Polson AP, Harrold CQ, Laster L. Guided tissue regeneration in human furcation defects after using a degradable barrier: A multi - center fea sibility study. Journal of Perio - dontol ogy 1995;66:377 - 385

- 53. Ah M, Johnson G, Kaldahl W, Patil K & Kalkwarf K. The effect of smoking on the response to periodontal therapy. Journal of Clinical Periodontology 1994:21:91 97
- 54. Raulin L, McPherson J, McQuade M, Hanson BG. The effect of nicotine on the attachment of human fibroblasts to glass and human root surfaces in vitro. Journal of Periodontology 1988;59:318 -325
- 55. Kenney EB, Kraal JH, Cahncellor MB, Bridges RB. Variations in the gingival polymorphonuclear leukocyte migration rate induced by tobacco smoke. Journal of Dental Research 1977:12:242 - 249
- 56. Baab DA, Oberg PA. The direct of cigarette smoking on gingival blood flow in humans. Journal of Perio dontology 1987;14:418 424
- 57. Rosen PS, Marks MH, Reynolds MA. Influence of smoking on long term clinical results of intrabony defects treated with regenerative therapy. Journal of Periodontology 1996:67:1159 1163
- 58. Westfelt E, Nyman S, Socransky S, Lindhe J. Significance of frequency of professional tooth cleaning on healing following periodontal surgery. Journal of Clinical Periodontology 1983;10:148 -156
- 59. Mellonig JT. Periodontal bone graft technique. International Journal of Periodontics and Restorative Dentistry 1990;10:288 - 299
- 60. McClain PK & Schallhorn RG. Long term assessment of combined

- osseous composite grafting, root conditioning, and guided tissue regeneration. International Journal of Periodontics and Restorative Dentistry 1993;13:8 27
- 61. Schultz AJ, Gager AH. Guided tissue regeneration using an absorbable membrane (polyglactin 910) and osseous grafting. International Journal of Periodontics and Restorative Dentistry 1990;10:8-17
- 62. Martin M, Gantes B, Garrett S, Egelberg J. Treatment of periodontal furcation defects.(I). Review of the literature and description of a regenerative surgical technique. Journal of Clinical Periodontology 1988;15:227 231
- 63. Caffesse R, Nasjleti C, Plotzke, A, Anderson G & Morrison E. Guided tissue regeneration and bone grafts in the treatment of furcation defects. Journal of

- Periodontology 1993;64: 1145 1153
- 64. Mellado JR, Salkin LM, Freedman AL, Stein MD. A comparative study of ePTFE periodontal membranes with and without decalcified freeze dried bone allografts for regeneration of interproximal intraosseous defects. Journal of Periodontology 1995;66: 751 755
- 65. Harris RJ. A clinical evaluation of guided tissue regeneration with a bioabsorbable matrix membrane combined with an allograft bone graft. a series of case reports. Journal of Periodontology 1997;68:598 607
- 66. Stahl SS, Froum S. Histologic healing response in human vertical lesions following the use of osseous allografts and barrier membranes. Journal of Clinical Periodontology 1991;18:149 152
- 67. Terranova VP, Franzetti LC, Hic S, DiFlorio RM, Lyall RM, Wikesjo UM, Baker PJ, Christersson LA, Genco RJ. A biochemical approach to periodontal regeneration: tetracycline treatment of dentin promotes fibroblast adhesion and growth. Journal of Periodontal Research 1986;21:330 337
- 68. Drury GI, Yukna RA. Histological evaluation of combining tetracycline and allogenic freeze dried bone on bone regeneration in experimental defects in baboons. Journal of Periodontology 1991;62:652 658
- 69. Yukna RA, Sepe WW. Clinical evaluation of localized periodontosis defects treated with freeze dried bone allografts combined with local and systemic tetracycline. International Journal of Periodontics and Restorative Dentistry 1982;2:8 21
- 70. Mabry TW, Yukna RA, Sepe WW. Freeze dried bone allografts combined with tetracycline in the treatment of juvenile periodontitis. Journal of Periodontology 1985;56: 74 80
- 71. Demolon IA, Persson GR, Ammons WF, Johnson RH. Effects of antibiotic treatment on clinical conditions with guided tissue regeneration: one year results. Journal of Periodontology 1994;65:713 717
- 72. Sander L, Voigt E, Frandsen G, Arnbjerg D, Warrer K, Karring T. Effect of local metronidazole application on periodontal healing following guided tissue regeneration. Clinical findings. Journal of Periodontology 1994;65:914 920
- 73. Mombelli A, Zappa U, bragger U, Lang NP. Systemic antimicrobial treatment and guided tissue regeneration. Clinical and microbio logical effects in furcation defects. Journal of Clinical Periodontology 1996;23:386 396
- 74. Nowzari H, Matian F, Slots J. Periodontal pathogens on polytetra fluoroethylene membranes for guided tissue regeneration inhibit healing. Journal of Clinical Periodontology 1995;22:469 474
- 75. Demolon IA, Persson GR, Moncla BJ, Johnson RH, Ammons WF. Effects of antibiotic treatment on clinical conditions and bacterial growth with guided tissue regeneration. Journal of Periodont ology 1993;64:609 616

- 76. Newman MG. The role of infection and anti-infection treatment in regenerative therapy. Journal of Periodontology 1993;64:1166 1170
- Cortellini P, Pini Prato G, Tonetti M. Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trial. Journal of Periodontology 1996;67: 217 - 223
- 78. Gottlow J, Laurell L, Lundgren D, Mathisen T, Nyman S, Rylander H & Bogentoft C. Periodontal Tissue response to a new bioresorbable guided tissue regeneration device: a longitudinal study in monkeys. International Journal of Periodontics and Restorative Dentistry 1994;14: 436 449
- Greenstein G, Caton J.
   Biodegradable barriers and guided tissue regeneration. Periodontol 2000 1993:1:36 45
- 80. Laurell L, Falk H, Fornell J, Johard G, Gottlow J. Clinical use of a biore sorbable matrix barrier in guided tissue regeneration therapy. case series. Journal of Periodontology 1994;65:967 975
- 81. Lundgren, D, Laurell L, Rylander H, Mathisen T, Nyman S & Rask M. The influence of the design of two different bioresorbable barriers on the results of guided tissue regeneration therapy. Journal of Periodontology 1995;66:605 -612
- 82. Becker W, Becker B, Mellonig J, Caffesse R, Warrer K, Caton J, Reid T. A prospective multi - center study evalu ating periodontal regeneration for class

- furcation invasions and intra bony defects after treatment with a bioab sorbable barrier membrane: 1 - year results. Journal of Periodont - ology 1996:67:641 - 649
- 83. Garrett S, Loos B, Chamberlain D, Egelberg J. Treatment of intraosseous periodontal defects with a combined adjunctive therapy of citric acid conditioning bone grafting, and placement of collagenous membranes. Journal of Periodontology 1988;15: 383 389
- 84. Bragger U, Hammerle CH, Mombelli A, Burgin W, Lang NP. Remodelling of periodontal tissues adjacent to sites treated according to the principles of Guide Tissue Regeneration(GTR). Journal of Clinical Periodontology 1992;19: 615 624
- 85. Tonetti MS, Cortellini P, Suvan JE, Adriaens P, Baldi C, Dubravec D, Fonzar A, Fourmousis I, Magnani C, Muller Campanile V, Patroni S, Sanz M, Vangsted T, Zabalegui I, Pini Prato G, Lang NP. Generalizability of the added benefits of Guided tissue regeneration in the treatment of deep intrabony defects. Evaluation in a multi center randomized controlled clinical trial. Journal of Periodont ology 1998;69:1183 1192
- 86. Mormann W, Ciancio S. Blood supply of human gingiva following periodontal surgery. Journal of Periodontology 1977;48:681 - 692
- 87. Parashis A, Andronikaki Faldami A, Tsiklakis K & Stelt P. Clinical appli caiton of a new bioresorbable guided tissue regeneration device: case reports. International Journal of Periodontics and

- Restorative Dentistry 1998;18:389 401
  88. Laurell L, Gottlow J, Mymand S, Falk H, Fornell J, Johard G. Gingival response to Guidor. a bioresorbable device in GTR therapy. Journal of Dental Research 1992;71(special issue):298
- 89. Zappa U, Caton J. Non resorbable and biodegradable barriers for regener ation in human periodontal defects. Journal of Dental Research 1992;71(special issue): 623

- Abstract -

Influence of Smoking on
Short - Term Clinical Results
of Periodontal Bone Defects
Treated with Regenerative
Therapy Using Bioabsorbable
Membranes

Tae - Heon Kang<sup>1</sup>, Yang - Jo Seol<sup>1</sup>, Yong -Moo Lee<sup>1</sup>, Seung - Beom Kye<sup>2</sup>, Weon - Kyeong Kim<sup>1</sup>, Chong - Pyoung Chung<sup>1</sup>, Soo - Boo Han<sup>1</sup>

 Department of Periodontology, College of Dentistry, Seoul National University
 Department of Periodontics, The Institute of Oral Health Science, Samsung Medical Center,

School of Medicine, Sungkyunkwan University

This study compared the short - term (4 months) clinical results of regenerative therapy with bioabsorbable membranes (BioMesh ) and bone allograft for the treatment of periodontal (intrabony and furcation) defects in smokers and non-smokers. (16 smokers) 32 subjects with 92 defects participated in the study (46 in smokers and 46 in non-smokers). This study also evaluated a bioresorbable barrier with and without decalcified freeze-dried bone allograft (DFDBA). The 92 periodontal defects were randomly treated with either

the resorbable barrier alone or resorbable barrier in combination with DFDBA follow - ing thorough defect debridement and root preparation with tetracycline. Each patient received both types of treatment modalities. Clinical examinations(probing depth, gingi - val recession, clinical attachment level, plaque index and gingival index) were carried out immediately before and 4 months after surgery.

Significant(p<0.001) gains in mean attachment level were observed for both smokers(2.93mm) and non-smokers(3.30mm) but there were not significant difference between two groups. Similarly, significant reductions in mean probing depthshowed for smokers (4.52mm) and non - smokers (4.26mm). However, when comparing gingival recession, smokers were found to exhibit significantly poorer treatment results (1.59mm vs 0.96mm, p<0.05). Using the split - mouth - design, no statistically significant difference between the two modalities could be detected with regard to pocket depth reduction, gingival recession, or attachment gain. These results illustrate that the attachment gain is better in the non - smoker and the best in the non-smoker with the combination therapy of resorbable barrier and DFDBA than with resorbable barrier alone but smoking had no significant effect on clinical treatment outcome, even though smokers show more significant gingival recession. In addition, both treatments, either resorbable barrier plus DFDBA or resorbable barrier alone, promoted significant resolution of periodontal defects but the addition of DFDBA with a bioabsorbable membrane

appears to add no extra benefit to the only membrane treatment.

Key words: bioabsorbable membrane; guided tissue regeneration; smoking; DFDBA; periodontal defect.

\*: Author of Correspondence